Header Logo

Connection

Doris Benbrook to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications Doris Benbrook has written about Ovarian Neoplasms.
Doris Benbrook
Connection Strength
4.106
Ovarian Neoplasms
  1. Platelet and epithelial cell interations can be modeled in cell culture, and are not affected by dihomo-gamma-linolenic acid. PLoS One. 2024; 19(8):e0309125.
    View in: PubMed
    Score: 0.615
  2. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
    View in: PubMed
    Score: 0.446
  3. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45.
    View in: PubMed
    Score: 0.350
  4. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
    View in: PubMed
    Score: 0.234
  5. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs. 2010 Mar; 21(3):297-305.
    View in: PubMed
    Score: 0.225
  6. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol. 2009 Dec; 115(3):438-42.
    View in: PubMed
    Score: 0.219
  7. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009 Aug 15; 69(16):6565-72.
    View in: PubMed
    Score: 0.216
  8. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther. 2007 Jun; 6(6):1814-22.
    View in: PubMed
    Score: 0.186
  9. Promise and problems of translational research. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S14-7.
    View in: PubMed
    Score: 0.178
  10. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. AAPS J. 2023 Dec 12; 26(1):5.
    View in: PubMed
    Score: 0.146
  11. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. Nutr Cancer. 2023; 75(2):662-669.
    View in: PubMed
    Score: 0.137
  12. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001 Apr 04; 93(7):516-25.
    View in: PubMed
    Score: 0.121
  13. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
    View in: PubMed
    Score: 0.118
  14. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
    View in: PubMed
    Score: 0.112
  15. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorg Med Chem. 2020 01 01; 28(1):115244.
    View in: PubMed
    Score: 0.111
  16. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 2019 May 15; 170:16-27.
    View in: PubMed
    Score: 0.105
  17. Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64.
    View in: PubMed
    Score: 0.099
  18. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
    View in: PubMed
    Score: 0.098
  19. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem. 2015; 96:209-17.
    View in: PubMed
    Score: 0.080
  20. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5.
    View in: PubMed
    Score: 0.075
  21. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):377-82.
    View in: PubMed
    Score: 0.070
  22. Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues. J Phys Chem B. 2006 Aug 17; 110(32):16124-30.
    View in: PubMed
    Score: 0.044
  23. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28.
    View in: PubMed
    Score: 0.041
  24. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007.
    View in: PubMed
    Score: 0.037
  25. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. Eur J Med Chem. 2018 Oct 05; 158:720-732.
    View in: PubMed
    Score: 0.025
  26. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.